Sihpromatum - I Grew my Boobs in China: Volume 1

Product Information

respectively) had significantly higher screening rates than women with lower education levels ( p<0. Data quality assurance for all registries were achieved through national criteria for Chinese cancer registration, including the comparability, completeness, and validity of data; only submissions considered of high quality were compiled in the cohort. The Kaplan–Meier method was used to generate survival curves, and the log-rank test was performed to compare unadjusted overall survival (OS) and disease-free survival (DFS) among the different patient groups. After data cleaning, 184,509 participants (including 109,317 females) were included in the basic database. Women with lower socioeconomic status had lower screening coverage, and there were still significant disparities across PLADs.

Second, we did not collect data on the status of pregnancy and child birth after breast cancer diagnosis. HRs estimated from multivariate Cox regressions were adjusted by year of diagnosis, age at diagnosis, area, stage, and molecular subtype. This approval is an important advance in the way breast cancer is classified and treated in China and supports our vision to bring Enhertu to more patients worldwide.For patients receiving endocrine therapy, the longer the duration of endocrine therapy, the better the prognosis. In addition, there is a need for the strengthening of health education and the improvement of accessibility to health services.

The combined SOFT and TEXT analysis showed that younger women under 35 years of age benefited the most from OFS treatment compared to other age groups, and that OFS combined with AI resulted in a 55% relative reduction in the risk of distant recurrence in patients under 35 years of age compared to tamoxifen alone.Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. The analysis showed a decreasing trend in the percentage of urban patients and an increasing trend in the rural patients. The incidence rate of young breast cancer increases by approximately 2% annually, while in older women, the rate of increased only slightly and even declined in those older than 65 years ( Fig.

Some reviews were about fertility in young patients, and some focused on the epidemiological and clinicopathological features. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. No difference was seen in OS by year, however, there was a significant difference in DFS by year ( P ＜ 0. Continuous variables, such as age and number of treatments, were expressed as medians (IQR, interquartile range) because they do not meet the assumption of normality. The demographic characteristics of patients from hospital-based cohort were consistent with those of population-based cohort.I didn’t catch the travel bug on my own, it was more like my family stuck it in my back pocket and I’ve been stuck with it ever since. Young breast cancer cases increased from approximately 10,000 in early-2000s to 13,422 in 2017 ( Fig. Treatment efficacy, adherence, and quality of life among women younger than 35 Years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. Sales of Enhertu in China are recognised by AstraZeneca and will be recorded as product sales on the profit and loss statement.